SMART Fellow
Redirecting to an External Platform
Senior Principle Investigator, Director of Institute of Cancer Research, SZBL
Cancer Biology, Immunology, Cancer Immunotherapy
2025 - PresentShezhen Bay Laboratory Senior Principal Investigator, Director of Institute of Cancer Research
2009-2025University of California, San Diego (UCSD) Distinguished Professor (with tenure)
2005-2009Burnham Institute for Medical Research, La Jolla, CA Professor
2000-2005Burnham Institute for Medical Research, La Jolla, CA Associate Professor
1999Department of Biochemistry and Molecular Biology, Indiana University School of Medicine Associate Professor
1994-1999Department of Biochemistry and Molecular Biology, Indiana University School of Medicine Assistant Professor
1991-1994Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada Postdoctoral
1990-1991Research Institute, The Hospital for Sick Children, Toronto, Canada Postdoctoral
1986-1990Indiana University Bloomington, Indiana Ph.D.,(Molecular Biology)
1982-19852nd Medical University of Army, China M.Sc., (Immunology)
1978-1982Hangzhou University, Hangzhou, China B.Sc., (Biology)
（1）Liver cancer development and recurrence in association with aging and the immune-suppressing microenvironment. The research group is using multidisciplinary approaches including single cell RNA- sequencing and spatial - omics.
（2）The mechanism of treatment-associated adverse effect in the elderly.
（3）Development of immunotherapy based on lipid nanoparticles that encapsulate immunoregulatory reagents.
（4）They will continue to investigate the structure, components, and functions of the“intercellsomes”in cancer recurrence associated with drug resistance developed in therapy.
2025 appointed as the Section Editor of the Editorial Board of FRONTIERS OF MEDICINE
2024 Outstanding Contribution Award from the US-China Association for Science and Technology
2023-2024 President, American Chinese Association of Cancer Research (ACACR)
2023 President-elect of the Society of Chinese Bio-scientists in America
2022 Chinese American diabetes association (CADA)
2015 Elected Fellow, American Association for the Advancement of Science (AAAS)
1.YL Liu, X Wang, N Krishnan, T HSiao, YC Ji, K kenako, MG Teneche, PD Adams, E Zuniga, SM Kaech, LF Zhang and GS Feng. Efficacious suppression of primary and metastasized liver tumors by polyIC-loaded nanoparticles.Hepatology,Accepted, 2025.
2.WS Chen, Y Liang, M Zong, JJ Liu, K Kaneko, KL Hanley, K Zhang, andGS Feng. Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment.Cell Reports,2021 Vol. 37 Issue 6 Pages 109974
3.Liang, Y, K Kaneko, B Xin, J Lee, X Sun, K Zhang, andGS Feng. Temporal analysis of postnatal liver development and maturation by single cell transcriptomics.Developmental Cell.57, 398-414, 2022
4.K Kaneko, Y Liang, Q Liu, S Zhang, A Scheiter, D Song, andGS Feng. Identification of CD133+ intercellsomes in intercellular communication to offset intracellular signal deficit.eLife.12, Epub on Oct 17, 2023. Accession Number: 37846866, DOI: 10.7554/eLife.86824
5.Bard-Chapeau EA, S Li, J Ding, SS Zhang, HH Zhu, F Princen, DD Fang, T Han, B Bailly-Maitre, V Poli, NM Varki, H Wang andGS Feng.PTPN11/Shp2acts as a tumor suppressor in hepatocellular carcinogenesis.Cancer Cell19, 629-639, 2011.
6.Feng GS, CC Hui, and T Pawson. SH2-containing phosphotyrosine phosphatase as a target of protein-tyrosine kinases.Science259, 1607-11, 1993.